Percy Carter, PhD, is Global Head of Discovery Sciences (DS) where he develops and drives the global small molecule discovery strategy for the Janssen early research portfolio.
He leads a global organization of 700+ employees who comprise five key functions: Computational Sciences; Discovery Chemistry; Drug Metabolism & Pharmacokinetics; Lead Discovery; and Core Business Services. Percy works in collaboration with TA discovery scientists and other stakeholders to define and operationalize innovative strategies for the successful identification and optimization of novel leads into drug candidates to fill the Janssen pipeline. He ensures alignment with Therapeutic Area (TA) priorities and Janssen R&D imperatives.
Prior to his role with Janssen, Percy was Senior Vice President and Head of Discovery for Bristol-Myers Squibb (BMS). Prior to that, he was Senior Vice President and Head of Discovery Chemistry & Molecular Technologies and was also Site Lead for the Biocon-BMS R&D Center in Bangalore, India. Percy began his career as a Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals (1999 – 2001) and joined BMS when the company acquired DuPont in 2001. During his combined time at BMS and DuPont, he collaborated with a wide range of colleagues to help build the immunoscience pipeline. In 2013, after moving into a cross-therapeutic area role, Percy worked on advancing the portfolio and driving innovation in supporting technologies, non-traditional modalities, and novel external partnerships.
Percy is the inventor or co-inventor on more than 25 U.S. patents and has authored or co-authored more than 75 peer-reviewed research publications.
He received his bachelor’s degree in Organic Chemistry from Dartmouth College, his Ph.D. in Chemistry & Chemical Biology from Harvard University, and completed a post-doctoral fellowship at Harvard Medical School and Massachusetts General Hospital. In 2014, he received his M.B.A. from the Massachusetts Institute of Technology.